查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球精准肿瘤学市场趋势与成长机会
市场调查报告书
商品编码
1389139

全球精准肿瘤学市场趋势与成长机会

Global Precision Oncology Market Trends and Growth Opportunities
出版日期: | 出版商: Frost & Sullivan | 英文 78 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

官民合作关係增加了精准肿瘤学的取得和普及，增加了综合服务和解决方案的潜力

根据患者的遗传倾向准确识别生物标记相关的过程很复杂，并且依赖参与配对过程的肿瘤学家、决策支援科学家或其他医疗保健专业人员的专业知识和知识。精准肿瘤学旨在为肿瘤学家提供诊断、预后和治疗工具，以根据患者的基因组成製定治疗方案。

获取、储存和处理高品质的生物材料以及透过纵向资料收集有组织的临床资讯是一项挑战。在处理患者资料时，与医疗机构内外的分析平台同意并安全地共用敏感资料是真正的问题。人工智慧、机器学习、机器人和基于巨量资料的多组体学工具等新技术正在促进和提高标靶治疗的准确性和发展。

需要进行广泛的肿瘤分析来识别准确的遗传生物标记和可操作的标靶。准确的诊断对于为患者提供个体化治疗至关重要。确定可以预测患者治疗反应和副作用发生的特定生物标记物，并确定哪些亚群将从特定治疗方法中受益至关重要。这有助于考虑遗传倾向。

精准肿瘤学改变了临床试验的设计，催生了基于精准诊断的测试，例如伞式测试和篮式测试。这些试验根据促癌因素的异常而不是癌症的类型来治疗患者。最新的类型是 N-of-1 试验，通常称为以患者为中心的试验，它评估患者特定的治疗方法组合。

精准肿瘤学涉及仔细监测，以评估肿瘤对治疗的反应，并在预期出现抗药性时改变治疗方法。治疗后也可以透过分子检测来检测抗药性突变。使用血浆循环性肿瘤细胞cDNA 分析进行非侵入性疾病负担监测是革命性的。

这项研究揭示了当前的技术趋势，并强调了为确保更多癌症患者很快就受益于精准肿瘤学所做的多学科努力。它还强调了关键的市场驱动因素和驱动因素、合作伙伴关係以及影响市场成长的当前和未来的市场趋势。产业使用案例可让您快速了解致力于开发精准肿瘤学颠覆性技术和药物的改变游戏规则的参与公司。这项研究根据临床需求、使用案例、商业模式、预防医学、打入市场策略和技术趋势为市场提供了新的成长机会。

目录

战略问题

  • 为什么成长如此困难？
  • The Strategic Imperative 8（TM）
  • 三大战略挑战对全球精准肿瘤产业的影响
  • 成长机会推动Growth Pipeline Engine（TM）

成长机会分析

  • 分析范围
  • 全球癌症负担
  • 精准肿瘤学途径
  • 精准肿瘤学概述 - 从患者到标靶治疗的开发
  • 影响精准肿瘤学进展的因素
  • 推动精准肿瘤学采用的主要趋势与策略
  • 精准肿瘤学商业模式 - PPP
  • 精准肿瘤学商业模式 - 公司策略
  • 生长促进因子
  • 成长抑制因素
  • 精准肿瘤供应商生态系统

精准肿瘤学研究与开发

  • 挑战 - 研究与开发
  • 概述-标靶药物开发流程
  • 精准肿瘤学检测
  • 下一代精准肿瘤学测试
  • 将基因组筛检纳入临床试验的潜在好处
  • 精准肿瘤学研究和发展的未来策略

推动精准肿瘤学研究和开发的国家倡议

  • 体学主导-倡议
  • 政府主导的搜寻精准肿瘤临床试验倡议- Canadian Precision Oncology Trial Finder
  • 推进精准肿瘤学测试的学术支持计划 - MatchMiner

精准肿瘤筛检、诊断、预后及治疗选择

  • 挑战 - 高精准度诊断、预后预测、治疗选择
  • 概述 - 精准癌症筛检、诊断、预后、治疗选择
  • 精准诊断、预后预测和治疗选择的未来策略

精准肿瘤监测及存活护理

  • 挑战 - 监测和倖存者护理
  • 概述 - 影响癌症存活照护的关键因素
  • 癌症倖存者的长期照护管理
  • 癌症治疗的未来策略

体学和资讯学在推进精准肿瘤学中不断变化的作用

  • 挑战-体学与资讯学
  • 体学和资讯学的优势
  • 体学管道 - 来自多组体学平台的资讯流
  • 多组体学分析在精准肿瘤学的应用
  • 资讯学在精准肿瘤学的应用
  • 人工智慧在精准肿瘤学的应用

创新企业

  • 罗氏集团（瑞士）
  • 产业使用案例与分析师观点
  • Caris生命科学（美国）
  • 产业使用案例与分析师观点
  • Acrivon Therapeutics（美国）
  • Massive Bio（美国）
  • 产业使用案例与分析师观点
  • 波士顿基因（美国）
  • 产业使用案例与分析师观点
  • Outcomes4Me（美国）
  • 产业使用案例与分析师观点

成长机会领域

  • 成长机会 1 - 用于治疗计划和选择的人工智慧
  • 成长机会 2 – 扩大治疗诊断的采用
  • 成长机会3 - 综合癌症资料平台
  • 成长机会 4 - PPP 模式拓展亚太地区精准肿瘤学
  • 图表列表
  • 免责声明
简介目录
Product Code: PF69-52

Public-private Partnerships Will Propel Access and Adoption of Precision Oncology Enhancing the Potential for Integrated Services and Solutions

The procedure for accurately identifying a biomarker correlation based on a patient's genetic makeup is complex and relies on the expertise and knowledge of an oncologist, decision-support scientist, or other healthcare professional involved in the matching process. Precision oncology aims to provide oncologists with diagnosis, prognosis, and treatment tools to tailor the treatment according to patients' genetic makeup.

Acquiring, storing, and processing high-quality biomaterials and collecting organized clinical information with longitudinal data sets is a challenge. Consent and securely sharing sensitive data with analytical platforms within and outside healthcare organizations are practical problems when dealing with patient data. Emerging technologies such as AI, ML, robotics, and big data-based multi-omics tools are enabling and improving the precision and development of targeted treatments.

Extensive tumor profiling is required for the identification of accurate genetic biomarkers and actionable targets. Accurate diagnosis is crucial for implementing personalized treatment for patients. It is crucial to identify specific biomarkers that can predict both the response to treatment and the occurrence of adverse effects in patients, to determine the subpopulation that would benefit from a particular therapy. This helps to account for genetic predisposition.

Precision oncology has changed clinical trial design, resulting in precision diagnostics-based studies such as umbrella trials and basket trials. These studies treat patients based on their oncogenic driver aberration, not their cancer kind. The most recent type is N-of-1 studies, often called patient-centered trials, which assess patient-specific therapy combinations.

Precision oncology uses careful monitoring to assess tumor response to therapy and change therapeutic actions if drug resistance is anticipated. Post-treatment molecular testing may detect resistance mutations. Noninvasive disease burden monitoring using plasma circulating tumor cell cDNA analysis is a breakthrough.

This study highlights current technological trends and emphasizes the interdisciplinary efforts underway to ensure that a greater number of cancer patients can benefit from precision oncology soon. The study also highlights some of the key market drivers and restraints, partnerships, and present and future market trends that affect the growth of the market. Industry use cases will provide brief insights into some of the game-changing participants who are working toward developing disruptive technologies and drugs for precision oncology. The study will provide emerging growth opportunities for the market based on clinical need, use cases, business models, preventive care, market access strategies, and technology trends.

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Global Precision Oncology Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Scope of Analysis
  • The Global Cancer Burden
  • Precision Oncology Pathway
  • Overview of Precision Oncology-From the Patient to the Development of Targeted Therapeutics
  • Factors Impacting the Advancement of Precision Oncology
  • Key Trends and Strategies Driving Precision Oncology's Implementation
  • Precision Oncology Business Model-PPPs
  • Precision Oncology Business Model-Strategies by Different Players
  • Growth Drivers
  • Growth Restraints
  • Precision Oncology Vendor Ecosystem

Precision Oncology R&D

  • Challenges-R&D
  • Overview-Targeted Drug Development Process
  • Precision Oncology Trials
  • Next-generation Precision Oncology Trials
  • Potential Advantages of Incorporating Genomic Screening in Clinical Trials
  • Future Strategies for Precision Oncology R&D

Country-level Initiatives to Drive Precision Oncology R&D

  • PPP-driven Initiative To Promote Precision Oncology-Omico
  • A Government-backed Initiative To Promote Precision Oncology Trials-Canadian Precision Oncology Trial Finder
  • Academic-backed Initiative To Promote Precision Oncology Trials-MatchMiner

Precision Oncology Screening, Diagnosis, Prognosis and Treatment Selection

  • Challenges-Precision Diagnostics, Prognosis, and Treatment Selection
  • Overview-Precision Cancer Screening, Diagnosis, Prognosis, and Treatment Selection
  • Future Strategies for Precision Diagnostics, Prognosis, and Treatment Selection

Precision Oncology Monitor and Survivorship Care

  • Challenges-Monitor and Survivorship Care
  • Overview-Key Factors Impacting Cancer Survivorship Care
  • Long-term Care Management for Cancer Survivors
  • Future Strategies for Cancer Care

Evolving Role of Omics and Informatics in Advancing Precision Oncology

  • Challenges-Omics and Informatics
  • Advantages of Omics and Informatics
  • The Omics Pipeline-The Information Flow from Multiomics Platforms
  • The Application of Multi-omics Analysis in Precision Oncology
  • The Application of Informatics in Precision Oncology
  • The Application of AI in Precision Oncology

Innovative Companies Propelling Precision Oncology

  • Roche Group, Switzerland
  • Industry Use Case and Analyst Perspective
  • Caris Life Sciences, United States
  • Industry Use Case and Analyst Perspective
  • Acrivon Therapeutics, United States
  • Massive Bio, United States
  • Industry Use Case and Analyst Perspective
  • BostonGene, the United States
  • Industry Use Case and Analyst Perspective
  • Outcomes4Me, United States
  • Industry Use Case and Analyst Perspective

Growth Opportunity Universe

  • Growth Opportunity 1-AI for Treatment Planning and Selection
  • Growth Opportunity 2-The Increasing Adoption of Theranostics
  • Growth Opportunity 3-Integrated Cancer Data Platforms
  • Growth Opportunity 4-The PPP Model Will Scale Precision Oncology in APAC
  • List of Exhibits
  • Legal Disclaimer